HealthTech Earnings Alert: Open Before Close (April 27th)
April 27th, 2022 (Earnings Report)Dear Reader,We just identified several healthtech stocks that are expected to release earnings starting today.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Align Tech
Symbol: ALGN
Recent Price: $$375.40
Average Analyst Price Target: $590.78 (57.37%)
Market Cap: $$29.58B
Last Year's EPS: $2.49
Consensus EPS Forecast: $2.3
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Kevin Caliendo, analyst at UBS, reiterates coverage on Align Tech (ALGN) in the Healthcare sector with a Buy rating and a price target of $ 500 (1 day ago).
TipRanks.com also reports that Align Tech currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $590.78 . The target pricing ranges from a high forecast of $722.00 down to a low forecast of $500.00. Align Tech (ALGN)’s last closing price was $$375.40 which would put the average price target at 57.37% upside.Here are 3rd party ratings for ALGN:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 30% (176 out of 253)
--------------------------------------------------------------------------
BioMarin Pharmaceutical
Symbol: BMRN
Recent Price: $$79.77
Average Analyst Price Target: $113.42 (42.18%)
Market Cap: $$14.75B
Last Year's EPS: $0.09
Consensus EPS Forecast: $0.2
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on BioMarin Pharmaceutical (BMRN) in the Healthcare sector with a Buy rating and a price target of $ 113 (2 days ago).
TipRanks.com also reports that BioMarin Pharmaceutical currently has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $113.42 . The target pricing ranges from a high forecast of $155.00 down to a low forecast of $90.00. BioMarin Pharmaceutical (BMRN)’s last closing price was $$79.77 which would put the average price target at 42.18% upside.Here are 3rd party ratings for BMRN:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Bottom 45% (139 out of 253)
--------------------------------------------------------------------------
Boston Scientific
Symbol: BSX
Recent Price: $$43.76
Average Analyst Price Target: $50.18 (14.67%)
Market Cap: $$62.55B
Last Year's EPS: $0.37
Consensus EPS Forecast: $0.39
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Danielle Antalffy, analyst at Leerink Partners, reiterates coverage on Boston Scientific (BSX) in the Healthcare sector with a Hold rating and a price target of $ 45 (1 week ago).
TipRanks.com also reports that Boston Scientific currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $50.18 . The target pricing ranges from a high forecast of $55.00 down to a low forecast of $45.00. Boston Scientific (BSX)’s last closing price was $$43.76 which would put the average price target at 14.67% upside.Here are 3rd party ratings for BSX:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Bottom 28% (182 out of 253)
--------------------------------------------------------------------------
Encompass Health
Symbol: EHC
Recent Price: $$66.10
Average Analyst Price Target: $79.40 (20.12%)
Market Cap: $$6.57B
Last Year's EPS: $1.05
Consensus EPS Forecast: $0.91
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: David S, analyst at Truist Financial, reiterates coverage on Encompass Health (EHC) in the Healthcare sector with a Buy rating and a price target of $ 85 (2 weeks ago).
TipRanks.com also reports that Encompass Health currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $79.40 . The target pricing ranges from a high forecast of $85.00 down to a low forecast of $75.00. Encompass Health (EHC)’s last closing price was $$66.10 which would put the average price target at 20.12% upside.Here are 3rd party ratings for EHC:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Bottom 16% (213 out of 253)
--------------------------------------------------------------------------
Icon
Symbol: ICLR
Recent Price: $$214.96
Average Analyst Price Target: $289.22 (34.55%)
Market Cap: $$17.53B
Last Year's EPS: $2.06
Consensus EPS Forecast: $2.69
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Timothy Daley, analyst at Wells Fargo, reiterates coverage on Icon (ICLR) in the Healthcare sector with a Hold rating and a price target of $ 250 (2 days ago).
TipRanks.com also reports that Icon currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $289.22 . The target pricing ranges from a high forecast of $325.00 down to a low forecast of $250.00. Icon (ICLR)’s last closing price was $$214.96 which would put the average price target at 34.55% upside.Here are 3rd party ratings for ICLR:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 14% (217 out of 253)
--------------------------------------------------------------------------
IQVIA Holdings
Symbol: IQV
Recent Price: $$214.41
Average Analyst Price Target: $278.00 (29.66%)
Market Cap: $$40.93B
Last Year's EPS: $2.18
Consensus EPS Forecast: $2.42
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Timothy Daley, analyst at Wells Fargo, reiterates coverage on IQVIA Holdings (IQV) in the Healthcare sector with a Hold rating and a price target of $ 235 (2 days ago).
TipRanks.com also reports that IQVIA Holdings currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $278.00 . The target pricing ranges from a high forecast of $313.00 down to a low forecast of $231.00. IQVIA Holdings (IQV)’s last closing price was $$214.41 which would put the average price target at 29.66% upside.Here are 3rd party ratings for IQV:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 32% (173 out of 253)
--------------------------------------------------------------------------
Merit Medical Systems
Symbol: MMSI
Recent Price: $$65.93
Average Analyst Price Target: $75.20 (14.06%)
Market Cap: $$3.73B
Last Year's EPS: $0.52
Consensus EPS Forecast: $0.47
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Michael Petusky, analyst at Barrington, reiterates coverage on Merit Medical Systems (MMSI) in the Healthcare sector with a Buy rating and a price target of $ 82 (1 week ago).
TipRanks.com also reports that Merit Medical Systems currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $75.20 . The target pricing ranges from a high forecast of $82.00 down to a low forecast of $72.00. Merit Medical Systems (MMSI)’s last closing price was $$65.93 which would put the average price target at 14.06% upside.Here are 3rd party ratings for MMSI:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 30% (176 out of 253)
--------------------------------------------------------------------------
Viking Therapeutics
Symbol: VKTX
Recent Price: $$2.29
Average Analyst Price Target: $19.40 (747.16%)
Market Cap: $$177.19M
Last Year's EPS: -$0.19
Consensus EPS Forecast: -$0.19
Expected Earnings Date: Apr 26 2022
Recent Analyst Action: Justin Zelin, analyst at BTIG, reiterates coverage on Viking Therapeutics (VKTX) in the Healthcare sector with a Buy rating and a price target of $ 20 (1 month ago).
TipRanks.com also reports that Viking Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.40 . The target pricing ranges from a high forecast of $28.00 down to a low forecast of $10.00. Viking Therapeutics (VKTX)’s last closing price was $$2.29 which would put the average price target at 747.16% upside.Here are 3rd party ratings for VKTX:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 45% (139 out of 253)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com